Optimer Spells Out Plans For Further Dificid Penetration
This article was originally published in The Pink Sheet Daily
Optimer Pharmaceuticals outlined its commercial strategy for recently launched antibiotic Dificid. The company plans to concentrate on long-term care facilities and proving that the drug is preferable over potential generic competition.
You may also be interested in...
The drug developer appears to be making the case for premium pricing by differentiating fidaxomicin for its ability to sustain clinical response and cut costs associated with recurrence.
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.